Healthcare
Hypera S.A.(HYPMY)
Live Price
Offline$3.81
-4.03% today
Window Change
-12.41%
Window
May 29, 2026 β Jun 18, 2026
- Market Cap
- $15.85B
- Revenue Growth
- +3.4%
- EPS Growth
- -10.8%
- Dividend Yield
- 5.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars Β· May 29, 2026 β Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Hypera S.A. (HYPMY) is a Healthcare stock with a market cap of $15.85B and listed on OTC. The stock last traded around $3.81 and down 12.4% across the available one-year price window (May 29, 2026 β Jun 18, 2026). Baseline metrics include revenue growth of +3.4%, EPS growth of -10.8%, a dividend yield of 5.0%. What stands out right now is revenue +3.4%, EPS -10.8%, free cash flow +0.4% with operating margin 28.5% and ROIC 9.2%. The dividend matters to the case here, with a current yield around 5.0%. Valuation is more restrained than many high-expectation growth names at P/E 8.5 and price/sales 1.8. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines HYPMY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+3.4% vs +7.6% peer median
Operating Margin
Above sector median
+28.5% vs +19.4% peer median
P/E
Below sector median
8.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 21, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +3.4% and EPS is at -10.8%, with operating margin around 28.5%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 5.0%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
HYPMY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HYPMY
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HYPMY Max Drawdown
-12.41%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HYPMY and SPY.
Company Overview
Hypera S.A.
Other OTC
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex Β A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, BiotΓ΄nico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo QuΓmica, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in SΓ£o Paulo, Brazil.
- Leadership
- Breno Toledo Pires de Oliveira
- IPO Date
- Oct 15, 2010
- Employees
- 10.5k
- Street Address
- Av. MagalhΓ£es de Castro, 4800
- Mailing
- SΓ£o Paulo, SP, 05676-120
- Region
- SΓ£o Paulo, SP, BR
- Reporting Currency
- USD
- Investor Line
- 55 11 3627 4206
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 8.5
- EV/EBITDA
- 8.1
- Price/Sales
- 1.8
- Price/Book
- 1.0
Growth
- Revenue
- +3.4%
- EPS
- -10.8%
- Free Cash Flow
- +0.4%
Profitability
- Gross Margin
- 59.0%
- Operating Margin
- 28.5%
- Net Margin
- 19.5%
- ROE
- 13.2%
- ROIC
- 9.2%
Balance Sheet
- Debt/Equity
- 0.62
- Current Ratio
- 1.95
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.